

Scientific Programme

Monday, 21 September 2015

09:00 - 10:00

Workshops and Courses, Room 2

Career Workshop with Peggy McKee I

09:00 - 10:00

Resumes - 3 Simple Changes to Get More Interviews

P. McKee, Career Confidential, Gunter, United States

10:15 - 11:15

Workshops and Courses, Room 2

Career Workshop with Peggy McKee II

10:15 - 11:15

Job Search Solutions - Where Are the Hidden Jobs?

P. McKee, Career Confidential, Gunter, United States

11:30 - 12:30

Workshops and Courses, Room 2

Career Workshop with Peggy McKee III

11:30 - 12:30

Job Interviews - How to Get More Offer

P. McKee, Career Confidential, Gunter, United States

13:30 - 14:30

Workshops and Courses, Room 2

Career Workshop with Peggy McKee IV

13:30 - 14:30

How to Get a Promotion

P. McKee, Career Confidential, Gunter, United States

14:45 - 15:45


Workshops and Courses, Room 2

Career Workshop with Peggy McKee V

14:45 - 15:45

Older Job Seekers - What You Need to Know About Age and Your Job Search


P. McKee, Career Confidential, Gunter, United States



Scientific Programme


Tuesday, 22 September 2015

	Scientific Forum, Room 1
08:30 - 12:00	Peptide Therapeutics T. Vorherr, Novartis Pharma AG, Basel, Switzerland E. Kitas, Roche Innovation Center, Basel, Switzerland R. Stocklin, Atheris SA, Geneva, Switzerland
08:30 - 09:30	Peptides as molecular interactors E. Giralt, Institute for Research in Biomedicine, Scientific Parc Barcelona, Barcelona, Spain
09:30 - 10:00	Coffee Break
10:00 - 10:30	(Glyco)Protein ligation enabled by the controlled cleavage of peptide bonds D. MacMillan, University College London, London, United Kingdom
10:30 - 11:00	Laser-Printed High Density Peptide Microarrays for Peptide Target Binder Discovery and Optimization V. Stadler, Pepperprint GmbH, Heidelberg, Germany
11:00 - 11:30	Phage selection of bicyclic peptides for application as therapeutics C. Heinis, EPFL, Lausanne, Switzerland
11:30 - 12:00	Tailoring semisynthetic ligands to investigate and regulate ErbB receptor family dysregulation in cancer C. Kroll, F. Hoffmann La-Roche, Basel, Switzerland
	Scientific Forum, Room 2
08:30 - 12:00	Digital Health & Care B. Hofrichter, ConCeplus GmbH, Weggis, Switzerland P. Dümmler, Switzerland
08:30 - 08:35	Intro / Welcome B. Hofrichter, ConCeplus GmbH, Weggis, Switzerland
08:35 - 09:00	An Outlook on Digital Health & Care by 2030 B. Hofrichter, ConCeplus GmbH, Weggis, Switzerland T. Wilckens, Innventis, Munich, Germany
09:00 - 09:30	Title to be Confirmed R. Herzog, HiMSS Europe, Berlin, Germany
09:30 - 10:00	Personalized Medicine - Future developments R. Barker, Precision Medicine Catapult, Innovate UK, Swindon, United Kingdom
10:00 - 10:30	Coffee Break



Scientific Programme

10:30 - 10:50	<p>Title to be Confirmed M.E. Petersen, Sundhed, Copenhagen, Denmark</p>
10:50 - 11:10	<p>How digital technologies will revolutionize pharmaceutical clinical trials A. Brown, Novartis Pharma AG, Basel, Switzerland</p>
11:10 - 12:00	<p>Panel Discussion D. Selz, Squirro AG, Zurich, Switzerland R. Barker, Precision Medicine Catapult, Innovate UK, Swindon, United Kingdom M.E. Petersen, Sundhed, Copenhagen, Denmark A. Brown, Novartis Pharma AG, Basel, Switzerland C. Biermann, Diaverum Group, Munich, Germany E. Georgiew, SEMASU Ltd., Eching, Germany R. Herzog, HiMSS Europe, Berlin, Germany T. Wilckens, Innventis, Munich, Germany</p>
Scientific Forum, Room 4	
08:30 - 12:00	<p>Synergy Forum G. Ulrich-Merzenich, University Clinic Bonn, Bonn, Germany D. Simeon-Dubach, Medservice, Switzerland</p>
08:30 - 09:00	<p>Pharmacokinetic profiling for discovering synergies and antagonisms of herbs and drugs V. Butterweck, University of Applied Sciences Northwestern Switzerland, Muttenz, Switzerland</p>
09:00 - 09:30	<p>From Additivity to Synergism C. Ritz, University of Copenhagen, Frederiksberg, Denmark</p>
09:30 - 10:00	<p>Coffee Break</p>
10:00 - 10:30	<p>High-throughput combinatorial screening R. Guha, National Center for Advancing Translational Sciences, Bethesda, United States</p>
Scientific Forum, Room 5	
08:30 - 12:00	<p>Drug Discovery Sciences SLAS C. Fattinger, Roche Innovation Center, Basel, Switzerland G. Cutler, Novartis Pharma AG, Basel, Switzerland</p>
08:30 - 09:00	<p>Droplet Interface Bilayers: new tools for ion-channel screening M. Wallace, University of Oxford, Oxford, United Kingdom</p>
09:00 - 09:30	<p>Micro-nano opportunities in bioanalytics: molography, plasmonic particle based single cell analytics, and miniaturized immunofiltration J. Voeroes, ETH Zurich, Zurich, Switzerland</p>




Scientific Programme

09:30 - 10:00	<p>Binding studies of type I, II, and III kinase inhibitors against Bcr-Abl kinase using back-scattering interferometry: a tale of allostery S.R. Weinberger, Molecular Sensing Inc., Los Gatos, United States</p>
10:00 - 10:30	Coffee Break
10:30 - 11:00	<p>Title to be Confirmed V. Myer, Editas Medicine, Cambridge, United States</p>
11:00 - 11:30	<p>Phenotypic Drug Discovery: discovering medicine based on disease biomarkers M. Prunotto, Roche Innovation Center, Basel, Switzerland</p>
11:30 - 12:00	<p>Combination of flow cytometry-based phenotypic screening and smart compound selection for rapid identification of novel cell cycle inhibitors L. Brault, Exquiron Biotech AG, Reinach, Switzerland</p>
Education Forum, Room 3	
09:00 - 12:00	<p>Jumpstarting Innovation S. Emmerth, iNet Innovation Networks Switzerland, Basel, Switzerland A. Moeri, Swiss Innovation Park NWCH, Basel, Switzerland B. Bhullar, Novartis Pharma AG, Basel, Switzerland C. Kloepper, iNet Innovation Networks Switzerland, Basel, Switzerland</p>
09:00 - 09:15	<p>Welcome and Introduction B. Bhullar, Novartis Pharma AG, Basel, Switzerland S. Emmerth, iNet Innovation Networks Switzerland, Basel, Switzerland</p>
09:15 - 09:30	<p>Swiss Innovation Park: An Introduction A. Moeri, Swiss Innovation Park NWCH, Basel, Switzerland</p>
09:30 - 10:00	<p>Title to be Confirmed C. Adams, Cydan Development, Cambridge, United States</p>
10:00 - 10:30	Coffee Break
10:30 - 11:00	<p>Title to be Confirmed S. Møller, Novo Seeds, Hellerup, Denmark</p>
11:00 - 11:30	<p>Breakout Labs: Catalyzing groundbreaking science out of the laboratory and into the economy H. Parthasarathy, Breakout Labs, San Francisco, United States</p>
11:30 - 12:00	Q&A
Vendor Exhibition, Hall 4.1	
10:00 - 17:00	Vendor and Poster Exhibition



Scientific Programme

- 12:30 - 13:30** Industry Symposium, Room 1
Shared Innovation in Drug Discovery: European Lead Factory
- 12:30 - 13:30** Workshops and Courses, Room 2
Career Workshop with Peggy McKee VI
- 12:30 - 13:30**
Networking for Career Success
 P. McKee, Career Confidential, Gunter, United States
- 12:30 - 13:30** Industry Symposium, Room 3
Industry Symposium "Making the Jump": BioJump & US Embassy
- 12:30 - 13:30** Industry Symposium, Room 4
Industry Symposium: Promega
- 12:30 - 12:40**
Reporter Bioassays to Assess Therapeutic Antibodies in Development for Immunotherapy Programs
 M. Cong, Promega R&D, United States
- 13:30 - 14:20** Keynote, Room 5
Welcome Words / Keynote Lecture 1 J.-P. Clozel, Actelion
- Welcome Words**
 B. Bhullar, Novartis Pharma AG, Basel, Switzerland
- From a start-up to a middle sized biopharmaceutical company: what did I learn?**
 J.-P. Clozel, Actelion Pharmaceuticals Ltc., Allschwil, Switzerland
- 14:30 - 17:00** Scientific Forum, Room 1
Peptide Therapeutics
- T. Vorherr, Novartis Pharma AG, Basel, Switzerland
 E. Kitas, Roche Innovation Center, Basel, Switzerland
 R. Stocklin, Atheris SA, Geneva, Switzerland
- 14:30 - 15:00**
Computational Tools for Predicting the Permeability of Peptides
 M. Schaefer, Novartis Pharma AG, Basel, Switzerland



Scientific Programme

15:00 - 15:30 **Uncovering the principles that drive passive membrane permeability in meso-MW compounds: Tackling a rich chemical space with new and used paradigms**
S. Lokey, University of California Santa Cruz, Santa Cruz, United States

15:30 - 16:00 **Coffee Break**

16:00 - 16:30 **Cellular peptide entry - induced versus constitutive permeability**
R. Brock, Radboud University Medical Centre, Nijmegen, Netherlands

16:30 - 17:00 **Sequence-defined oligomers containing natural and artificial oligo-amino acids for intracellular drug, protein and nucleic acid delivery**
E. Wagner, Ludwig-Maximilian University Munich, Munich, Germany

Education Forum, Room 3

14:30 - 16:30 **Jumpstarting Innovation**
S. Emmerth, iNet Innovation Networks Switzerland, Basel, Switzerland
A. Moeri, Swiss Innovation Park NWCH, Basel, Switzerland
B. Bhullar, Novartis Pharma AG, Basel, Switzerland
C. Kloepper, iNet Innovation Networks Switzerland, Basel, Switzerland

14:30 - 15:00 **NEOMED: a network of SMEs under one roof - all engaged in drug discovery**
M. Fehlmann, NEOMED, Montreal, Canada

15:00 - 15:30 **Title to be Confirmed**
K. Hertogs, Johnson & Johnson Innovation, London, United Kingdom

15:30 - 16:00 **Title to be Confirmed**
M. Pritchard, Allied Minds, Boston, United States


16:00 - 16:30 **Patient-driven ALS drug development - innovation by collaboration**
I. de Greef-van der Sandt, Treeway, Rotterdam, Netherlands
B. Müller, Treeway, Rotterdam, Netherlands

Scientific Forum, Room 4

14:30 - 17:00 **Synergy Forum**
G. Ulrich-Merzenich, University Clinic Bonn, Bonn, Germany
D. Simeon-Dubach, Medservice, Switzerland


14:30 - 14:45 **PI3K and DNA repair - point of convergence?**
K. Zmajkovicova, Universitat Basel, Basel, Switzerland

14:45 - 15:00 **Screening of synergic interactions of anti-angiogenic and anti-tumor compounds**
M



Scientific Programme

- 15:00 - 15:15** **Synergism research: a tool for the study of pharmacology and toxicology of herbal medicinal products**
O. Kelber, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany
- 15:15 - 15:30** **Gene expression profiling as a promising approach for justifying fixed drug combination products**
O. Kelber, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany
- 15:30 - 16:00** **Coffee Break**
- 16:00 - 16:30** **Title to be Confirmed**
H. Schweim, University of Bonn, Bonn, Germany
- Scientific Forum, Room 5
- 14:30 - 17:00** **Drug Discovery Sciences SLAS**
C. Fattering, Roche Innovation Center, Basel, Switzerland
G. Cutler, Novartis Pharma AG, Basel, Switzerland
- 14:30 - 15:00** **Title to be Confirmed**
J. Wingfield, AstraZeneca, Cambridge, United Kingdom
- Coffee Break**
- 15:00 - 15:30** **High fidelity small molecule DNA-encoded yoctoreactor libraries**
L.K. Petersen, Vipergen ApS, Copenhagen, Denmark
- Keynote, Room 5
- 17:15 - 18:00** **Innovation Keynote Lecture - Peter Thiel, Thiel Capital**
B. Bhullar, Novartis Pharma AG, Basel, Switzerland
C. Kloepper, iNet Innovation Networks Switzerland, Basel, Switzerland
- Welcome Reception, Hall 4.1
- 18:00 - 19:00** **Welcome Reception**



Scientific Programme

Wednesday, 23 September 2015

08:30 - 12:00

Scientific Forum, Room 1

Peptide Therapeutics

T. Vorherr, Novartis Pharma AG, Basel, Switzerland
 E. Kitas, Roche Innovation Center, Basel, Switzerland
 R. Stocklin, Atheris SA, Geneva, Switzerland

08:30 - 09:30

Guanylate Cyclase-C Agonists for Treatment of Gastrointestinal Disorders and Inflammatory Bowel Diseases

K. Shailubhai, Synergy Pharmaceuticals Inc., New York, United States

09:30 - 10:00

Coffee Break

10:00 - 10:30

Structure-guided optimization and design of a novel peptidomimetic scaffold: Discovery of novel small-molecule adenain inhibitors

E. Altmann, Novartis Pharma AG, Basel, Switzerland

10:30 - 11:00

Drug delivery and release systems for targeted tumor therapy

A. Beck-Sickinger, University of Leipzig, Leipzig, Germany

11:00 - 11:30

Tumor-penetrating peptides in the targeting of drugs and theranostic nanoparticles

E. Ruoslahti, Sanford-Burnham Medical Research Institute, La Jolla, United States

11:30 - 12:00

Enhanced Paracellular Transport of Insulin Can Be Achieved Via Transient Induction of Myosin Light Chain Phosphorylation

R. Mrsny, University of Bath, Bath, United Kingdom

08:30 - 12:00

Scientific Forum, Room 4

Infectious Diseases

D. Ritz, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
 U. Jenal, University of Basel, Basel, Switzerland
 G. Dernick, Roche Innovation Center, Basel, Switzerland

Title to be Confirmed

J. Rolff, Free University Berlin, Berlin, Germany

Coffee Break

Title to be Confirmed


C. Zumbunn, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

Title to be Confirmed

M. Devocelle, Royal College of Surgeons in Ireland, Dublin, Ireland


Title to be Confirmed

B. Ernst, University of Basel, Basel, Switzerland




Scientific Programme

	Scientific Forum, Room 2
09:00 - 12:00	Stem Cells in Biomedicine R. Heilker, Boehringer Ingelheim, Biberach, Germany C. Cusulin, Roche Innovation Center, Basel, Switzerland C. Hippert, Roche Innovation Center, Basel, Switzerland
09:00 - 09:30	Title to be Confirmed R. Passier, Leiden University, Leiden, Netherlands
09:30 - 10:00	Title to be Confirmed M. Peschanski, iStem, Evry Cedex, France
10:00 - 10:30	Coffee Break
10:30 - 11:00	Title to be Confirmed M. Kraus, Nestle institute of Health Sciences, Lausanne, Switzerland
11:00 - 11:30	Title to be Confirmed J. Schwamborn, University of Luxembourg, Esch-sur-Alzette, Luxembourg
11:30 - 12:00	Title to be Confirmed R. Ali, University College London, London, United Kingdom
	Scientific Forum, Room 5
09:00 - 12:00	Next Generation Sequencing C. Mason, Cornell University, New York, United States J. Dudley, Icahn School of Medicine at Mount Sinai, New York, United States B. Bhullar, Novartis Pharma AG, Basel, Switzerland
09:00 - 09:30	Non-reproducibility of large-scale drug screening B. Haibe-Kains, Princess Margaret Cancer Centre, Toronto, Canada
09:30 - 10:00	NGS and Drug Safety Prediction N. Tatonetti, Columbia School of Medicine, New York, United States
10:00 - 10:30	Coffee Break
10:30 - 11:00	The Signature Program - A Novel trial model for rapid signal finding studies in a molecularly pre-selected patient population B. Kang, Novartis Pharma AG, East Hanover, United States
11:00 - 11:30	Bioinformatics solutions for 100,000 genomes A. Rendon, Genomics England Ltd., London, United Kingdom
11:30 - 12:00	Meeting the challenge of genomics data storage and security D. Fortune, Baseport, Calgary, Canada




Scientific Programme

	Scientific Forum, Room 3
09:30 - 12:00	Medicinal Chemistry J. Harris, cjh consultants, Eynsford, United Kingdom A. Hersey, EMBL-EBI, Hinxton, United Kingdom
09:30 - 10:00	Sharing pharma compounds with academia: experiences with providing vitamin D receptor ligands S. Hackethal, Charite Berlin, Berlin, Germany
10:00 - 10:30	Coffee Break
10:30 - 11:00	Title to be Confirmed L. Frye, Schrodinger, Portland, United States
11:00 - 11:30	Title to be Confirmed A. Pannifer, University of Dundee, Dundee, United Kingdom
11:30 - 11:45	PQR309: A potent, brain-penetrant, dual Pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability F. Beaufils, PIQUR Therapeutics AG, Basel, Switzerland
	Vendor Exhibition, Hall 4.1
10:00 - 17:00	Vendor and Poster Exhibition
	Industry Symposium, Room 1
12:30 - 13:30	Industry Symposium: Czech Embassy
	Industry Symposium, Room 2
12:30 - 13:30	Industry Symposium: British Embassy
	Industry Symposium, Room 3
12:30 - 13:30	Industry Symposium: Takara-Clontech
	Industry Symposium, Room 4
12:30 - 13:30	Industry Symposium: Molecular Devices
	Keynote, Room 5
13:30 - 14:15	Keynote Lecture 2 - J. Reed, Roche




Scientific Programme

- 13:30 - 13:40** **Title to be Confirmed**
J. Reed, F. Hoffmann-La Roche, Basel, Switzerland
- 14:15 - 17:30** **GPCR**
Scientific Forum, Room 4
R. Bouhelal, Novartis Pharma AG, Basel, Switzerland
X. Leroy, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- 14:15 - 14:30** **Introduction to the Forum**
R. Bouhelal, Novartis Pharma AG, Basel, Switzerland
X. Leroy, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- 14:30 - 15:00** **Disease modulation of GPCR oligomer expression in the brain**
F. Ciruela, University of Barcelona, Barcelona, Spain
- 15:00 - 15:30** **Towards the development of a PET radioligand for the in vivo imaging of cannabinoid receptor subtype 2 (CB2)**
R. Slavik, ETH Zurich, Zurich, Switzerland
- 15:30 - 16:00** **Coffee Break**
- 16:00 - 16:30** **G protein-coupled receptor structures and their implications for structure-based drug discovery**
V.-P. Jaakola, Novartis Pharma AG, Basel, Switzerland
- 16:30 - 17:00** **Structure Based Drug Discovery with Stabilised G Protein-Coupled Receptors**
C. Fiez-Vandal, Heptares Therapeutics, Welwyn Garden City, United Kingdom
- 17:00 - 17:15** **Label free technologies to study interactions of human adenosine A2A receptor in detergent and membrane environment**
S. Huber, F. Hoffmann - La Roche, Basel, Switzerland
- 17:15 - 17:30** **Activation of G-protein-coupled receptors correlates with the formation of a continuous internal water pathway**
S. Yuan, Actelion Pharmaceutical Company, Allschwil, Switzerland
- 14:30 - 17:00** **Peptide Therapeutics**
Scientific Forum, Room 1
T. Vorherr, Novartis Pharma AG, Basel, Switzerland
E. Kitas, Roche Innovation Center, Basel, Switzerland
R. Stocklin, Atheris SA, Geneva, Switzerland
- 14:30 - 15:00** **Dalazatide, a first-in-class blocker of the Kv1.3 potassium channel on effector memory T cells: safety, tolerability and proof of concept immunomodulation in patients with active plaque psoriasis**
S. Iadonato, Kineta Inc., Seattle, United States



Scientific Programme

- 15:00 - 15:30** **ARG011 a clinical candidate for the buccal delivery of Exenatide using ArisCrown Technology**
P. Botti, Arisgen, Geneva, Switzerland
- 15:30 - 16:00** **Coffee Break**
- 16:00 - 16:30** **A breakthrough technology for sublingual delivery of peptides, proteins and immune-therapies**
Y. Decadt, Biologus, Hergiswil, Switzerland
- 16:30 - 17:00** **Biophysical characterization of lipidated peptides and its interaction with serum albumin**
S. Kanai, F. Hoffmann-La Roche, Basel, Switzerland
- Scientific Forum, Room 2
- 14:30 - 16:00** **Stem Cells in Biomedicine**
R. Heilker, Boehringer Ingelheim, Biberach, Germany
C. Cusulin, Roche Innovation Center, Basel, Switzerland
C. Hippert, Roche Innovation Center, Basel, Switzerland
- 14:30 - 15:00** **Title to be Confirmed**
H. Semb, University of Copenhagen, Copenhagen, Denmark
- 15:00 - 15:30** **Title to be Confirmed**
M. Lutolf, EPFL, Lausanne, Switzerland
- 15:30 - 16:00** **Title to be Confirmed**
T. Schroeder, ETH Zurich, Zurich, Switzerland
- Scientific Forum, Room 3
- 14:30 - 17:00** **Medicinal Chemistry**
J. Harris, cjh consultants, Eynsford, United Kingdom
A. Hersey, EMBL-EBI, Hinxton, United Kingdom
- 14:30 - 15:15** **Title to be Confirmed**
J. Overington, EMBL-EBI, Cambridge, United Kingdom
- 15:15 - 16:00** **Title to be Confirmed**
C. Lipinski, Melior Discovery, Exton, United States
- Scientific Forum, Room 5
- 14:30 - 17:00** **Next Generation Sequencing**
C. Mason, Cornell University, New York, United States
J. Dudley, Icahn School of Medicine at Mount Sinai, New York, United States
B. Bhullar, Novartis Pharma AG, Basel, Switzerland




Scientific Programme

14:30 - 15:00	Title to be Confirmed E. Elhaik, University of Sheffield, Sheffield, United Kingdom
15:00 - 15:30	The Targeted Locus Amplification (TLA) Technology for targeted complete NGS sequencing & haplotyping. M. van Min, Cergentis, Utrecht, Netherlands
15:30 - 16:00	Integrating Genotype Protocols into Disease Management C. DesRosiers, CareMed Pharmaceutical Services, Lake Success, United States
16:00 - 16:30	Coffee Break
16:30 - 17:00	The Extreme Microbiome Project S. Tighe, University of Vermont, Burlington, United States

Interactive Poster Session, Hall 4.1

Interactive Poster Session



Scientific Programme

Thursday, 24 September 2015

08:30 - 12:00

Scientific Forum, Room 1

Aging and Drug Discovery

A. Zhavoronkov, Insilico Medicine, Baltimore, United States
 B. Bhullar, Novartis Pharma AG, Basel, Switzerland

08:30 - 09:00

Intro

B. Bhullar, Novartis Pharma AG, Basel, Switzerland

09:00 - 09:30

Aging Research: 1985-2015

G. Martin, University of Washington School of Medicine, Seattle, United States

09:30 - 10:00

Rapalogs as antiaging drugs: Are we there yet?

B. Kennedy, Buck Institute for Research on Aging, Novato, United States

10:00 - 10:30

Coffee Break

10:30 - 11:00

Title to be Confirmed

J. Campisi, Buck Institute for Research on Aging, Novato, United States

11:00 - 11:30

Title to be Confirmed

G. Fuellen, Rostock University Medical Center, Rostock, Germany

11:30 - 12:00

In silico approaches to geroprotector screening

A. Zhavoronkov, Insilico Medicine, Baltimore, United States

08:30 - 12:10

Scientific Forum, Room 4

GPCR

R. Bouhelal, Novartis Pharma AG, Basel, Switzerland
 X. Leroy, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland

08:30 - 09:00

Matching orphan ligands to membrane receptors

F. Bassilana, Novartis Pharma AG, Basel, Switzerland

09:00 - 09:30

Biased agonism: Consequences for clinical candidates

C. Cowan, Trevena Inc., King of Prussia, United States

09:30 - 10:00

Coffee Break

10:00 - 10:30

FPR2/ALXR agonists: discovery, characterization and application

O. Corminboeuf, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

10:30 - 11:00


Elucidation of the Interactome of G Protein Coupled Receptors in Hypothalamic Weight Regulation

H. Biebermann, Charité Berlin, Berlin, Germany

11:00 - 11:30


Fluorescent biosensors for multicolored views of GPCR signaling.

T. Hughes, Montana Molecular, Bozeman, United States



Scientific Programme

- 11:30 - 11:45** **Adenosine receptors as a target in colonic inflammation**
K. Nieber, Institute for Pharmacy, Leipzig University, Leipzig, Germany
- 11:45 - 12:00** **Short Talk: Multicolor fluorescent biosensors for multiplexed detection of GPCR receptor activation**
I. Ramos, Innoprot S.L., Derio, Spain
- 12:00 - 12:10** **Concluding remarks**
R. Bouhelal, Novartis Pharma AG, Basel, Switzerland
X. Leroy, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
- 08:30 - 12:00** Scientific Forum, Room 5
Next Generation Sequencing
Title to be Confirmed
T. Lappalainen, New York Genome Center, New York, United States
Epigenomic studies for biomarker discovery in hematological malignancies
M. Figueroa, University of Michigan Medical School, Ann Arbor, United States
- 08:45 - 12:00** Scientific Forum, Room 3
Medicinal Chemistry
J. Harris, cjh consultants, Eynsford, United Kingdom
A. Hersey, EMBL-EBI, Hinxton, United Kingdom
- 08:45 - 09:30** **Title to be Confirmed**
O. Tudor, University of New Mexico, Albuquerque, United States
- 09:30 - 10:00** **Title to be Confirmed**
D. Vitt, 4SC, Planegg-Martinsried, Germany
- 10:00 - 10:30** **Coffee Break**
- 10:30 - 11:00** **Title to be Confirmed**
J. Brown, Ubiquigent Ltd., Dundee, United Kingdom
- 11:00 - 11:30** **Title to be Confirmed**
G. Drewes, Cellzome GmbH, Heidelberg, Germany
- 09:00 - 12:00** Scientific Forum, Room 2
Translational Medicine
P. Groenen, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
O. Peter, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
J. Mosbacher, Roche Innovation Center, Basel, Switzerland




Scientific Programme

09:00 - 09:30	<p>Wanted: New concepts for personalized medicine G. Maass, F. Hoffmann-La Roche, Grenzach-Whylen, Germany</p>
09:30 - 10:00	<p>Swiss Personalized Health Initiative P. Meier-Abt, Swiss Academy of Medical Sciences, Basel, Switzerland</p>
10:00 - 10:30	<p>Coffee Break</p>
10:30 - 11:00	<p>Title to be Confirmed B. Munos, InnoThink Center for Research in Biomedical Innovation, Santa Monica, United States</p> <p>Precision Medicine: From concepts to concrete cases E. Gosber, PatientsLikeMe, Cambridge, United Kingdom</p>
10:00 - 17:00	<p>Vendor Exhibition, Hall 4.1</p> <p>Vendor and Poster Exhibition</p>
13:30 - 14:15	<p>Keynote, Room 5</p> <p>Keynote Lecture 3 - K. Asadullah, Charité</p>
13:30 - 13:40	<p>Trends in translation medicine: the value of external innovation K. Asadullah, Charité Medical Center, Berlin, Germany</p>
14:30 - 17:00	<p>Scientific Forum, Room 1</p> <p>Aging and Drug Discovery</p> <p>A. Zhavoronkov, Insilico Medicine, Baltimore, United States B. Bhullar, Novartis Pharma AG, Basel, Switzerland</p>
14:30 - 15:00	<p>Title to be Confirmed F. Frueh, Human Longevity Inc., San Diego, United States</p>
15:00 - 15:30	<p>First rating of drugs with geroprotective properties A. Moskalev, Institute of Biology of Komi Science Center of RAS, Syktyvkar, Russian Federation</p>
15:30 - 16:00	<p>Title and Speaker to be Confirmed</p>
16:00 - 16:30	<p>Coffee Break</p>
16:30 - 17:00	<p>Overview of Geroprotectors, Discovery Methods and Trends A. Roy, Biogerontology Research Foundation, Oxford, United Kingdom</p>



Scientific Programme

	Scientific Forum, Room 2
14:30 - 16:00	Translational Medicine P. Groenen, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland O. Peter, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland J. Mosbacher, Roche Innovation Center, Basel, Switzerland
14:30 - 15:00	MIDATA Personal Data Cooperatives - My Data Our Health E. Hafen, ETH Zurich, Zurich, Switzerland
15:00 - 15:30	Title to be Confirmed M. Wehling, University of Mannhiem, Mannheim, Germany
15:30 - 16:00	RDoC: Integrating genetics, imaging, cognitive sciences to transform Mental Health diagnosis and treatment B. Cuthbert, National Institute of Mental Health NIMH, Rockville, United States
	Oral Session - Best Abstracts, Room 3
14:30 - 17:15	Oral Session - Best Abstracts (various topics)
14:30 - 14:45	BMP-2 induces epithelial-to-mesenchymal transition and accelerates motility and invasiveness of breast cancer cells via depletion of pRb and up-regulation of CD44 H. Peide, Jinan University, Guangzhou, China
14:45 - 15:00	Antibody based targeting of beta-amyloid fragment fingerprints during early peptide oligomerization. A novel diagnostic and therapeutic tool for prodromal Alzheimer´s disease? A.W. Schmid, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
15:00 - 15:15	Improvement of mechanical properties of 3D printed hydroxyapatite scaffolds by culture of osteoblast-like cells under perfusion flow N. Rimmer, School of Life Sciences FHNW, Muttenz, Switzerland
15:15 - 15:30	Microscale hydrogel patterning to manipulate stem cell fate L. Kolb, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
15:30 - 15:45	Targeting FAK using inhibitors of protein-protein interactions P. Rondé, University of Strasbourg, CNRS UMR 7213, Illkirch, France
15:45 - 16:15	Coffee Break
16:15 - 16:30	Tetraiodothyroacetic acid-conjugated polyethylenimine for enhanced delivery of plasmid DNA via integrin receptor A. Dehshahri, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of
16:30 - 16:45	Single-cell resolution of emergent clones in the myelodysplastic syndromes during therapy and disease progression P. Vijay, Weill Cornell Medical College, New York, United States
16:45 - 17:00	Poster prize ceremony



Scientific Programme

Scientific Forum, Room 4

14:30 - 17:30

Signaling and Drug Resistance in Cancer

A. Soltermann, University of Basel, Basel, Switzerland
M. Hall, University of Basel, Basel, Switzerland

14:30 - 15:00

Title to be Confirmed

M. Wymann, University of Basel, Basel, Switzerland

15:00 - 15:15

Comprehensive profiling of signal transduction pathways in human tumours - bead-based Western blotting for characterising primary tumour tissue

M.F. Templin, NMI an der Universität Tübingen, Reutlingen, Germany

15:15 - 15:30

Dynamic visualisation of the PI3-kinase pathway

V. Hurst, Dept. Biomedicine, University of Basel, Basel, Switzerland

15:30 - 16:00

Coffee Break

16:00 - 16:30

A glycolytic shift as escape mechanism to anti-angiogenic therapy

G. Christofori, University of Basel, Basel, Switzerland

16:30 - 17:00

Title to be Confirmed

M. Bentjres-Ali, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

17:00 - 17:30

Title to be Confirmed

M. Hall, University of Basel, Basel, Switzerland